...
首页> 外文期刊>Clinical and vaccine immunology: CVI >Assessment of Imprecision in gamma interferon release assays for the detection of exposure to Mycobacterium tuberculosis.
【24h】

Assessment of Imprecision in gamma interferon release assays for the detection of exposure to Mycobacterium tuberculosis.

机译:对γ干扰素不精确的评估释放化验检测的接触结核分枝杆菌。

获取原文
获取原文并翻译 | 示例
           

摘要

New gamma interferon (IFN-gamma) release assays (IGRAs) to detect an exposure to Mycobacterium tuberculosis have recently been launched. The majority of the studies in temperate-climate countries agree that these methods have superior specificity and equal or even superior sensitivity over tuberculin skin tests (TSTs) in the diagnosis of latent tuberculosis (TB) infection (LTBI). However, reproducibility data of IGRAs are virtually missing. We assessed within-run, between-run, and total imprecision of two commercial IGRAs by testing samples from subjects with a stable state of TB infection or treated pulmonary TB, a sample from a healthy volunteer, and internal quality control samples. We calculated coefficients of variance (CV%s) to describe assays variability and compared the obtained results to the reported CV%s for other commercial immunodiagnostic methods. We illustrate an example of assay variability near the cutoff zone to demonstrate the necessity of a gray zone. Due to the strict adherence to the standard operation procedures (SOP) adopted in our laboratory, the total imprecision of enzyme-linked immunospot (ELISPOT)- and enzyme immunoassay (EIA)-based IGRAs was at a maximum CV% of 37.8% for the samples with moderate and high reactivities. Imprecision of testing samples with very low reactivity levels or nonreactive samples may, however, exceed 100%. In conclusion, despite multiple steps of the method performance, the analytical imprecision of IGRAs, which in our study design included also between-lot variability and had a component of normal biological variation, was well in accordance with the reported imprecisions of other manual immunodiagnostic tests. The recognition of the variability around the cutoff point advocates the use of a gray zone to avoid ambiguous result interpretations.
机译:新γ干扰素(IFN-gamma)释放化验(干扰素释放)检测结核分枝杆菌的风险敞口肺结核最近推出了。大多数研究温带国家一致认为,这些方法优越特异性和相等甚至优越结核菌素皮肤较敏感测试(测试)潜在的诊断结核病感染(LTBI)。干扰素释放几乎是缺失的。within-run between-run,总不精确两个商业干扰素释放试验样本受试者结核病感染或稳定状态的治疗肺结核,样本从健康志愿者和内部质量控制样品。我们计算系数的方差(CV % s)描述化验可变性和比较了结果为其他报告的CV % s商业immunodiagnostic方法。说明试验可变性附近的一个例子截止区来演示的必要性灰色地带。标准操作规程(SOP)采用我们实验室的总不精确有关酶联免疫斑点)酶联immunospot(和酶免疫测定(EIA)的干扰素释放最多CV % 37.8%的样品和温和高反应活性。很低或不反应的反应水平然而,样本可能超过100%。尽管多个步骤方法的性能,在我们的分析不精确的干扰素释放包括研究设计也在可变性和正常的一个组成部分生物变异,依照其他手册的报道不精确immunodiagnostic测试。在分界点提倡可变性使用一个灰色地带,避免模棱两可的结果解释。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号